Karman Holdings has fallen 16.5% in a single week, but the short sellers who might have caused that move are actually retreating — a divergence worth understanding.
The stock closed at $41.09 on September 1, down nearly 14.7% over the past month. That places it roughly 53% below the Street's mean price target of $87.10. Peers have felt sector pressure too, but nothing like this: KTOS slid 6.3% on the week and IA fell 13.7%, while HII actually gained 0.4%, highlighting that KRMN's move is company-specific rather than purely macro.
Short interest tells a less aggressive story than the price action implies. Shorts have been trimming, not building. SI has fallen 11.5% over the past week to 9.1% of the free float — still a meaningful level, but the direction of travel is clearly down from a peak near 10.7% in mid-August. Borrow conditions reflect the same easing tone: cost to borrow has drifted to around 0.51%, a low rate that has barely moved in weeks, and availability is loose at roughly 300% of current short interest. That means there are approximately three shares available to lend for every one already out on loan — no squeeze mechanics, no sign of a forced unwind. The ORTEX short score has eased from 62.9 on August 19 to 59.2 by September 1, confirming the fade in bearish conviction. Short interest ranks in the bottom 7th percentile of the ORTEX universe by short score, meaning the stock screens as highly shorted but not on a momentum-building trajectory.
Options positioning is modestly more cautious than usual, though not dramatically so. The put/call ratio of 1.12 runs slightly above its 20-day average of 1.08 — a z-score of just 0.55 — placing it well inside normal territory. What is notable is that the PCR has been persistently above 1.0 since late August after spending most of the prior week below it, which suggests investors have started adding downside protection as the stock fell but haven't panicked into extreme hedges. The 52-week PCR high is 5.77, so current levels are far from distressed.
The Street remains overwhelmingly bullish but has spent August slashing targets. After the most recent earnings print in early August, Truist trimmed its target from $118 to $85 while holding Buy; Evercore and Needham both cut to $80 from $100 and $125 respectively, also maintaining positive ratings. Only BWS Financial has a Sell with a $37 target — close to where the stock now trades. The consensus mean of $87.10 implies roughly 112% upside from current levels, but the direction of analyst revisions is clearly one-way. The bull case rests on 58% revenue growth and 30% EBITDA margins from the latest quarter, plus deep defense exposure in hypersonics and next-generation munitions. Bears flag cash burn, execution risk from a fast-moving acquisition strategy, and a valuation that — even after the selloff — still carries a PE above 58x and EV/EBITDA near 26x. EPS momentum scores remain strong in the 81st percentile over both 30 and 90 days, but the 12-month forward EPS growth estimate ranks in the bottom 17th percentile, reflecting how sharply analysts have trimmed outer-year projections. Institutional flows tell a mixed story: BlackRock added more than 5.5 million shares in the quarter to July, and State Street added 2.3 million, signaling large passive accumulation — but FMR has been trimming its 13G stake from 6.3% to 5.2% as recently as August 6.
Insider data is stale — the most recent SEC Form 4 filings date to December 2025, with the CEO and CFO both executing planned 10b5-1 sales at prices between $58 and $69. Those trades are too dated to read as a current signal and occurred well above today's price. The next earnings event is scheduled for November 6, and with the stock now trading near the lone Street bear's target, the Q3 print becomes a critical test of whether the bull case on margin expansion and backlog conversion can reassert itself after a summer of target cuts.
See the live data behind this article on ORTEX.
Open KRMN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
